A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Breast Cancer

Interventions

DRUG: PF-07220060 CDK4 inhibitor
DRUG: Fulvestrant
DRUG: Everolimus
DRUG: Exemestane

Sponsor

Pfizer